Participant-centric study design has advanced, but site-centric execution has not kept pace. In the Journal for Clinical Studies, Brian Mallon examines how unclear expectations, administrative burden and contract delays ...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Us and it
This article by Gerard Quinn, Vice President of IT Innovation and Informatics, which appeared in PharmaTimes Magazine, delves into how AI is transforming clinical trials by improving efficiency, accelerating timelines, and enhancing decisions across the clinical development process.
-
Streamlining bioprocesses with automation
In this article from BioPharm International, Ronan Fox, Senior Vice President, IT R&D, provides commentary on the evolving role of automation in biopharmaceutical development.
-
DCT Tracker: Charting the next chapter for decentralisation
More than four years after decentralisation became a necessity in the clinical trials space, the sector is still finding its way around decentralised clinical trials (DCTs). And like any other paradigm shift, the journey has taken several turns.
-
Human-enabled AI driving enhancements in clinical trial site selection
In this piece from Clinical Trial Vanguard, Travis Caudill, Vice President, Feasibility, Site Identification & Clinical Informatics explores the improvements in site selection that human-enabled AI is delivering.
-
ICON acquires HumanFirst to boost support for digital tools in clinical trials
This article from STAT covers ICON’s acquisition of HumanFirst, a cloud-based technology company supporting precision measurement in clinical trials. It features an interview with Andy Coravos, CEO of HumanFirst, who outlines how the acquisition will support sponsors to deploy better and more effective precision measurements into more clinical trials.
-
Keeping eCOAs off the critical path – key considerations
The prevalence of decentralised clinical trials and the importance of patient-centricity in medical practices are just two of many factors leading to the increased use of electronic Clinical Outcome Assessments (eCOAs). Digital devices like smartphones, tablets, wearables and web-based platforms are increasingly being used to measure the impact of a disease and/or treatment on patients’ quality of life and are an important way we can capture the patient’s voice in a clinical trial.
The eCOA system consists of the devices used for data collection, specialised eCOA software installed in these devices for collecting the data or access to web-based eCOA platforms and a centralised database or server to store, manage and analyse the data securely. This article explains how an optimised eCOA implementation strategy can minimise several risks and challenges associated with clinical trials.
Article published in International Pharmaceutical Industry, Volume 15 Issue 3, 29 September 2023
-
Patient-first technology development increasing patient centricity
This article by Carrye Nibblelink, Executive Director, Decentralised Clinical Trial Solutions in the Journal of mHealth explores how the ICON Digital Platform engages patients throughout their clinical trial journey.
Copyright 2023 The Journal of mHealth (Simidics Ltd)
-
The role of digital health technology tools in supporting medical adherence
In this article in Pharmaceutical Market Europe, Dr Peter Schueler and Dr Isaac R Rodriguez Chavez outline the role of digital health technology tools in supporting medical adherence. 2022 PM Group
-
How healthcare can develop through digital innovation
Gerard Quinn and Barbara Skerritt offer their insights into the rapid acceleration of digital innovation in clinical research in the past two years.
-
The waterfall effect of digital health technology on unifying healthcare and clinical research
Isaac R Rodriguez-Chavez contributes to the DPHARM Autumn 2021 newsletter, discussing the use of digital health to maximise efficiencies in decentralised clinical trials.
